Dr. Philip A. Salem is the innovator for the cancer treatment breakthrough made up of a concomitant combination of personalized Immunotherapy, Chemotherapy and Targeted therapy (‘ICTriplex Treatment’).
Although the medications he administers in this treatment are individually FDA approved, the overall concomitant therapy protocol is not. Patients who have been treated using ICTriplex have experienced more than 95% response rate, particularly in lung and pancreatic cancers.
Dr. Salem hopes that this treatment will be more widely available to those outside his clinic in the coming years, and he is working to educate the next generation of oncologists on this groundbreaking treatment in cancer medicine. To learn more, watch the video below: